TY - JOUR
T1 - Prevalence and characteristics of peanut allergy in US adults
AU - Warren, Christopher
AU - Lei, Dawn
AU - Sicherer, Scott
AU - Schleimer, Robert
AU - Gupta, Ruchi
N1 - Funding Information:
Disclosure of potential conflict of interest: R. S. Gupta reports receiving grants from the National Institutes of Health (grants R21 ID# AI135705, R01 ID# AI130348, and U01 ID# AI138907), Rho Inc, Stanford Sean N. Parker Center for Allergy Research, UnitedHealth Group, Thermo Fisher Scientific, Genentech, and the National Confectioners Association; and serves as a medical consultant/advisor for Before Brands, Kaléo Inc, Genentech, Institute for Clinical and Economic Review, Food Allergy Research and Education, Aimmune Therapeutics, and DBV Technologies. S. Sicherer reports royalty payments from UpToDate and from Johns Hopkins University Press; grants to his institution from the National Institute of Allergy and Infectious Diseases, from Food Allergy Research and Education, and from HAL Allergy; and personal fees from the American Academy of Allergy, Asthma and Immunology, outside of the submitted work. S. Sicherer was the American Academy of Pediatrics representative to the National Institute of Allergy and Infectious Diseases Expert Panel for peanut allergy guidelines and also co-author of American Academy of Pediatrics Clinical Reports regarding atopy prevention. R. Schleimer reports National Institutes of Health grant money paid to the institution and to himself, and consulting fees and/or stock ownership from Intersect ENT, GlaxoSmithKline, Allakos, Aurasense, Merck, BioMarck, Sanofi, AstraZeneca/Medimmune, Genetech, Exicure, Otsuka, Aqualung Therapeutics Corp, Actobio Therapeutics, Lyra Therapeutics, Astellas Pharm Inc, and Genzyme/Sanofi Corp; and has Siglec-8 and Siglec-8 ligand-related patents licensed to Allakos Inc. The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
Supported by grant R21AI135702-PI from the National Institute of Allergy and Infectious Diseases .
Publisher Copyright:
© 2021
PY - 2021/6
Y1 - 2021/6
N2 - Background: Peanut allergy (PA) is the leading pediatric food allergy and a common cause of anaphylaxis. Little is known, however, on the prevalence and characteristics of PA in the adult population and whether phenotypic differences exist between adult-onset and childhood-onset PA. Objectives: This study describes the current US population-level burden of adult PA. Methods: A cross-sectional food allergy survey was administered via phone and web in 2015 and 2016, resulting in nationally representative complex-survey weighted data for 40,443 adults. Reported food allergies were considered “convincing” if symptoms to specific allergens were consistent with an IgE-mediated reaction. Results: The prevalence of current self-reported PA was 2.9% among US adults, with 1.8% having convincing PA. Over 17% of adults with peanut allergy reported onset of their PA in adulthood. In adults with childhood-onset PA, 75.4% reported physician-diagnosed PA, compared with only 58.9% of adult-onset PA. Despite a similar frequency of food allergy–related emergency department visits within the past year (approximately 1 in 5 adults with PA allergy), adults with childhood-onset PA were significantly more likely to have a current epinephrine prescription compared with those with adult-onset PA (56% vs 44% respectively; P =.02) and were more likely to use an epinephrine autoinjector (48% vs 35%, P =.01). Conclusions: Approximately 4.6 million US adults have PA—over 800,000 of whom appear to have developed their PA after age 18 years. Further examination of phenotypic differences between childhood-onset and adult-onset PA may improve understanding and management of adult PA.
AB - Background: Peanut allergy (PA) is the leading pediatric food allergy and a common cause of anaphylaxis. Little is known, however, on the prevalence and characteristics of PA in the adult population and whether phenotypic differences exist between adult-onset and childhood-onset PA. Objectives: This study describes the current US population-level burden of adult PA. Methods: A cross-sectional food allergy survey was administered via phone and web in 2015 and 2016, resulting in nationally representative complex-survey weighted data for 40,443 adults. Reported food allergies were considered “convincing” if symptoms to specific allergens were consistent with an IgE-mediated reaction. Results: The prevalence of current self-reported PA was 2.9% among US adults, with 1.8% having convincing PA. Over 17% of adults with peanut allergy reported onset of their PA in adulthood. In adults with childhood-onset PA, 75.4% reported physician-diagnosed PA, compared with only 58.9% of adult-onset PA. Despite a similar frequency of food allergy–related emergency department visits within the past year (approximately 1 in 5 adults with PA allergy), adults with childhood-onset PA were significantly more likely to have a current epinephrine prescription compared with those with adult-onset PA (56% vs 44% respectively; P =.02) and were more likely to use an epinephrine autoinjector (48% vs 35%, P =.01). Conclusions: Approximately 4.6 million US adults have PA—over 800,000 of whom appear to have developed their PA after age 18 years. Further examination of phenotypic differences between childhood-onset and adult-onset PA may improve understanding and management of adult PA.
KW - Food allergy
KW - adult-onset food allergy
KW - atopy
KW - peanut allergy
KW - prevalence
UR - http://www.scopus.com/inward/record.url?scp=85101688517&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2020.11.046
DO - 10.1016/j.jaci.2020.11.046
M3 - Article
C2 - 33579526
AN - SCOPUS:85101688517
SN - 0091-6749
VL - 147
SP - 2263-2270.e5
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 6
ER -